Litcius/Paper detail

Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study

Amira Marouf, Anne‐Ségolène Cottereau, Salim Kanoun, P Deschamps, Michel Meignan, Patricia Franchi, David Sibon, Clara Antoine, Thomas Gastinne, Cécile Borel, Mohammad Hammoud, Guillaume Sicard, R. Gille, Doriane Cavalieri, Aspasia Stamatoullas, Lauriane Filliatre‐Clement, Julien Lazarovici, Adrien Chauchet, Luc‐Matthieu Fornecker, Sandy Amorin, Mathieu Rocquet, Nicole Raus, Barbara Burroni, Marie Thérèse Rubio, Didier Bouscary, Philippe Quittet, Olivier Casasnovas, Pauline Brice, Hervé Ghesquières, Jérôme Tamburini, Bénédicte Deau

2021Haematologica18 citationsDOIOpen Access PDF

Abstract

International audience

Topics & Concepts

Brentuximab vedotinMedicineAutologous stem-cell transplantationInternal medicineOncologyObservational studyTransplantationRefractory (planetary science)Stem cellCohortLymphomaHematopoietic stem cell transplantationCohort studyChemotherapyHodgkin lymphomaSurgeryGeneticsAstrobiologyBiologyPhysicsLymphoma Diagnosis and TreatmentViral-associated cancers and disordersChronic Lymphocytic Leukemia Research
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study | Litcius